NHS Breast Screening

[Martin Vickers in the Chair]

I beg to move, That this House has considered e petition 742179 relating to NHS breast screening.

It is a pleasure to serve under your chairmanship, Mr Vickers. I would like to start by thanking the petitioner, Gemma Reeves, for all the hard work she has put into starting the petition and gathering over 106,000 signatures from across the UK. The petition is titled “Lower the age for invites to regular mammograms to 40 & perform annually”, and says: “Lower the age for when you are first called to 40 and provide funding to carry out Mammograms Annually instead of every Three Years.

Early detection is key and the prevalence of Breast Cancer in young patients is rising.

I am a Chemotherapy Nurse and working in this Clinical Setting for 8 Years and I have seen a rise in Breast Cancer in Patients under the Age of 40 increase.

Early detection is key in identifying those Aggressive forms of Breast Cancer”.

This is an issue that many people here and outside the Chamber care deeply about. Breast cancer still affects too many women, and far too many women die from it every year. I had the privilege of meeting with Gemma, who is here today. She told me about her experience of being a nurse for 15 years, eight of which have been in oncology, and about her concerns from having seen a rise in breast cancer cases in younger women, especially since covid.

Breast cancer is the most common type of cancer for women in the UK—one in seven women may get it. As Gemma wrote in her petition, “Early detection is key”, and has led to improved recovery and survival rates. Over half of breast cancer cases occur in women outside the national screening age, and one in six occur in women under 50. Men, too, get breast cancer; however, they make up approximately 1% of all cases. Currently, the NHS invites women to come to their first breast screening between the ages of 50 and 53, and this goes on until they are 71. They are invited every three years, after which a woman can choose to continue going for mammograms, but will not be automatically invited. Although everyone is at risk of breast cancer, women are at a higher risk if they are over 50, have dense breast tissue, have a family history of breast or ovarian cancer, or have particular breast conditions, for example benign breast disease.

There is a breast screening pathway for those identified as NHS targeted very high risk. It is also important to note that NICE guidelines recommend annual mammography scans for women aged between 40 and 49 at moderate risk, as well as annual mammography or MRI surveillance for some high risk groups.

I commend the hon. Lady for securing this debate. Unfortunately, many women are diagnosed with this cancer each year. Invasive lobular breast cancer accounts for some 15% of all breast cancer cases, yet it is routinely missed until it reaches an advanced stage. Hundreds of members of this House have backed the call for a dedicated £20 million five year research investment into the fundamental biology of lobular cancers. Does the hon. Lady agree that the Minister—I believe she is sympathetic to this—must undertake to incorporate advanced screening technologies, such as contrast enhanced mammography or MRI, into the NHS pathway for women with dense breast tissue or a suspected lobular profile? The Government must grasp the issue and do something now.

I thank the hon. Member for his intervention. I, too, look forward to hearing the Minister’s response on that issue.

Some 1.94 million women between the ages of 50 and 70 were screened in 2024-25, and almost 20,000 cancers were detected. Cancers were detected in nine in every 1,000 women, which is a 16% increase on the previous year. Attendance to screening reached the highest level in a decade and has been championed by charities such as Breast Cancer Now, which shares public figures, stories and personal messages.

I thank the hon. Member for securing this important debate. Does she share my concern about the difference between the numbers of first time attendees to screening and returning attendees, at 89.1% and 63% respectively? Does she have a view on how we can increase the number attending their first screening?

Screening is key, and we have to be bolder and more inventive about how we get people along to screening. There have been many public health campaigns over the years. After a campaign, there is always a rise in attendance, but when the campaign stops, attendance falls again, so I agree that that is something that the Minister must look at.

The hon. Member for Bromley and Biggin Hill (Peter Fortune) makes a valid point. Is my hon. Friend aware that between 2020 and 2023, more than three in four women in Scotland took up their screening invitations? However, take up is varied based on deprivation: 64.2% of women in the most deprived areas attended, compared with 82.8% in the least deprived areas. Breast cancer survival rates reflect that; women from more deprived areas in particular are more likely to die at an earlier age, because they have not been for screening and are diagnosed late. Making screening available to people in innovative ways is important, but so too is screening people in their neighbourhoods. Does my hon. Friend agree?

I fully agree with my hon. Friend. Unfortunately, that is not just the case for breast screening; bowel cancer screening is lower in areas of economic and health deprivation. We must look at how we target those populations.

It is key that we continue to increase awareness of the importance of routine health appointments and modifiable risk factors. Although screening is increasing generally, the NHS breast screening programme found that one in three women still do not take up their offer of screening. As my hon. Friend said, it is key that we continue with strategies that promote the uptake of screening in areas of lower attendance such as by running awareness campaigns, sending reminder texts and deploying mobile screening units, among other strategies. In preparing for this debate, I met Breast Cancer Now, as well as CoppaFeel!, the UK’s only youth focused breast cancer awareness charity. They call for more screening of women who have a higher risk of breast cancer, as well as providing women identified with wraparound support.

Diagnostics are key to identifying those with breast cancer successfully, although mammography is not always the best diagnostic tool, particularly for younger women and those with dense breast tissue, so it is important to invest in other diagnostics, such as MRIs, and to consider their capacity to be scaled and expanded. Younger women tend also to have denser breasts, which mammograms are worse at analysing as the scans are harder to interpret. That can lead to women having repeated scans and extended investigations.

It is important to note that most European countries screen for breast cancer between the ages of 50 and 69, although there is some variation in age ranges and frequency, with countries such as Albania, Iceland and Sweden starting screening at 40. Although breast cancer diagnoses for women under 40 are rarer, and about 4% of breast cancer cases in the UK are in women under 40, when young women get breast cancer, they are much more likely than older women to have a family history of breast cancer and genetic mutations that are associated with increased risk.

There is an ongoing trial called AgeX, which is looking at the benefits of regularly screening women aged 47 to 49 and aged 71 to 73, given how little is known about screening women outside the ages of 50 to 70. The trial took place from 2009 until 2020, and 4 million women took part. The first report to come out of the trials is due in December 2026 and the final report is due in 2031, so it will be a few years before we know its findings. Other trials include the UK age trial, led by Professor Stephen Duffy, which looked into the effectiveness of annual mammographic screening for women in their 40s and found that the mortality benefit was greatest for the first decade after screening started.

I am proud to have Walk The Walk—one of the country’s leading breast cancer charities, which has raised a huge amount of money and awareness—in my constituency. It is pushing for mammogram testing to be extended. Does the hon. Lady agree that extending it to the under-40s and the over-70s could have a notable effect on fighting this deadly cancer?

I agree, and I look forward to hearing the Minister talk about how we can take this forward.

The UK National Screening Committee is still concerned about false positives, overdiagnosis and over treatment. In 2012, Sir Michael Marmot chaired an independent review of breast screening, which found that the current UK screening programme prevents about 1,300 deaths from breast cancer annually. However, he also found that overdiagnosis meant that, for every death prevented by screening, about three women are treated for a cancer that they do not have. As breast cancer is less common in younger women, there is a concern that overdiagnosis would be much higher in that age group. False positive results can induce long lasting anxiety and an unwillingness to attend future screenings. It is important that screening programmes accurately weigh up the balance between potential harms and benefits. I am sure we will hear more about that in the debate.

It is a common misconception that breast cancer is not a problem any more, but more women die from breast cancers than from other cancers. We need to do more to look after women in their 40s and women under 40. We need risk adapted screening to better improve our chances of early detection in the most vulnerable. I look forward to hearing from other Members and the Minister.

Order. I remind Members that they should bob if they wish to contribute—as they are doing. I will not impose a time limit at this stage. If you stick to about five minutes each, we should accommodate everyone.

It is a pleasure to serve under your chairmanship, Mr Vickers. I congratulate my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) on introducing the debate, and I thank everyone who signed the petition. Behind every signature is a person, a family member or a friend, who has faced the frightening possibility that cancer may be found too late. They may even have lost somebody because it was found far too late.

In Bawtry in my constituency, local people have painted the town pink over the last few years during Breast Cancer Awareness Month. They have also taken the time to promote a simple message inspired by the movie “Legally Blonde”: bend and check. It is a powerful reminder that awareness, confidence and early action can save lives. I am really glad that Epworth may also be turning the town pink later this year under Kim Penfold, who is getting shops to join in and turn their fronts pink to raise awareness of early detection and screening.

The petition calls for routine breast screening to begin at 40 and to take place annually. That is a serious and understandable ask, but we must be guided by the evidence as well as the strength of feeling. The current NHS programme invites women to be screened every three years from the age of 50 until their 71st birthday. The independent UK National Screening Committee has advised that, on the evidence currently available, lowering the age or increasing the frequency of screening could bring harm as well as benefits, as we heard from my hon. Friend. Mammograms can be less accurate for younger women with denser breast tissue, increasing the risk of false positives and unnecessary tests and treatment. However, UK Age trial findings from a study of 160,000 women over 20 years show that annual mammograms for women in their 40s significantly reduces breast cancer deaths, saving a life for 1,000 women screened—one life, millions of memories.

We cannot stand still. The question raised by this petition is therefore entirely legitimate. I would be grateful if the Minister confirmed when Parliament can expect the UK National Screening Committee to consider the final AgeX trial findings and how the evidence on additional screening for women with dense breast tissue will inform future decisions.

We must also focus on the women already entitled to screening, as about three in 10 eligible women do not take up their invitation. This Labour Government’s work on digital innovations, mobile units, targeted outreach and more accessible equipment is welcome, but it must reach women in deprived communities, rural areas and communities where uptake is at its lowest.

I recently visited the new breast care unit at County hospital, where Michelle Ellits and Mr Sekha Marla gave me a fantastic tour. One of the things they spoke about was having separate areas as people walk into the breast care unit for those who are having treatment for breast cancer and those who are there for a mammogram, because it scares women to go to the unit if they are not confident about what they are there for. Does my hon. Friend agree that although more scans, more mammograms and better support are important, something as fundamental as building design is integral in making sure that women take up the offer to get their mammogram?

My hon. Friend makes a valid point. The environment that people first walk into makes a massive difference in how they feel about their screening. I went to one of those units with my wife only a couple of weeks ago—she had a lump in her breast—and the warm welcome that she got as we walked in was so amazing; it put her at ease and it put me at ease so I could support her, and it made the whole experience as good as it could possibly be. I am also thankful to say that she is doing very well.

Will the Minister provide an update on what the Government are doing to ensure that the people who can already go for tests go for them? No woman should wait for a screening letter if she notices a lump, a change in shape, skin changes or anything that does not feel right. Whatever their age, they should contact their GP. Early diagnosis gives people more options, more time and often the chance to see children and grandchildren grow up. That is why this petition matters, and that is why, ultimately, we need to act on it.

It is a pleasure to serve under your chairship, Mr Vickers. I thank my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for her thoughtful opening remarks. I pay tribute to all those affected by breast cancer, those facing diagnosis, and their families, friends and carers who stand beside them. It is their experiences that make this debate so important. I also pay tribute to my constituents for signing this petition, and I thank the petitioner for starting it in the first place.

I welcome the Government’s ambition for the national cancer plan, which commits the NHS to ensuring that, by 2035, 75% of people diagnosed with cancer will be cancer free and living well five years after diagnosis. The plan will also develop further AI assisted interpretation of images for suspected breast cancer diagnosis, and it will help us to detect breast cancer in women under 50 with denser breast tissue.

Under the last Government, cancer performance targets had not been met since 2014, leaving too many women facing delays and poor health outcomes. However, I know that my constituents want this Government to go further and to include women aged 40 in routine invitations for breast cancer screening. According to CoppaFeel!, cases of breast cancer in under-50s are on the rise. A recent report states that we have seen a 5% increase in the last year. Patients under 50 are more likely to have their symptoms missed and to be diagnosed at a later stage in their cancer journey compared with those over 50.

That issue is even more pronounced for women from minority and ethnic backgrounds and for those from deprived and rural areas, who have less access to screening opportunities in their communities. Additional public health attention needs to be paid to that. According to Breast Cancer Research, those groups are 10% more likely to begin treatment after the cancer has already become invasive and 20% more likely to require a mastectomy.

To achieve our cancer outcome aspirations, I ask the Minister to extend routine mammogram invitations to women from the age of 40. I hope she will also consider the roll out of alternative diagnostic measures that will affect the diagnosis of younger women.

It is a pleasure to serve under your chairmanship, Mr Vickers. I thank the hon. Member for North Ayrshire and Arran (Irene Campbell) for introducing this important debate on behalf of the Petitions Committee, of which I am also a member. Cancer is an issue that touches most of us, nearly every single day. No doubt we will all have had a friend or family member with cancer, and I am grateful that this petition has given us the opportunity to debate such an important issue.

This is an extremely poignant debate for me, as I lost two friends to cancer at the end of last year: Russell Brown, who served the Worth Valley as a district councillor on Bradford council, and Chris Graham, a former Keighley town councillor who served the Longley and Parkwood wards. Their recent losses are still felt very much across the communities that I am lucky enough to represent.

We have rightly had several recent opportunities to debate the issue of cancer, but today’s debate is particularly important, as breast cancer is the most common cancer diagnosed in women in the United Kingdom and the second most common cancer overall, with around 60,000 new cases and 11,200 deaths each year. That equates to about 31 deaths every single day, which is far too many.

This important petition calls for early diagnosis, which is crucial. According to Cancer Research UK, 76.6% of women survive for 10 years or more after being diagnosed, and 85% of those are diagnosed at an early stage. I agree with the petition, and I thank Gemma Reeves for starting it, as well all those who kindly put their name to it, including from across my constituency.

It is right to call for early screening at the age of 40. There is compelling evidence that early detection saves lives. Breast cancers identified at an early stage are genuinely smaller and less likely to have spread, and they require less aggressive treatment. Early diagnosis and early screening are key. Early diagnosis can not only improve survival rates, but it reduces the physical and psychological burden associated with advanced diagnosis and the disease spreading.

It is equally important, however, to acknowledge that screening for breast cancer is not a one size fits all approach. Screening for younger women generally produces less accurate mammograms because the tissue is denser, making cancers more difficult to detect and increasing the risk of false positives, but it should still happen. I repeat the petitioners’ call for early diagnosis. It is incredibly important.

My sister was diagnosed with breast cancer at the age of 36. She has been through chemotherapy, radiotherapy and surgery, and I am pleased to say that she is on the mend, but that is another example of someone being diagnosed before the age of 40. If there is an historical family association with breast cancer, those under 40 should have the opportunity for early diagnosis. I agree with the petitioners that having a repeat opportunity of screening for annual check ups rather than every three years is important.

Access to screening is not just about age; it is about ensuring that those who are eligible for screening are aware of it and choose to take part. I have major concerns about the lack of uptake across certain groups. There is 81% uptake for breast cancer screening in the least deprived areas, compared with 56% in the most deprived areas. I know that the Minister cares deeply about the issue and I commend her for her work on it; the cause is close to her heart. I would be keen to understand from her how the Government are looking to tackle that discrepancy. I would also like to understand whether there is a plan to roll out an annual screening programme rather than just a three yearly one.

Ultimately, I know that all hon. Members participating in the debate share the objectives of reducing deaths from breast cancer and ensuring that women receive the best possible care, but they cannot be achieved without a fully funded long term workforce plan, alongside a clear, funded milestone to show how and when patients will see improvement.

I put on record my thanks to the volunteers, campaigners and professionals, including the mobile cancer screening units that operate in my constituency of Keighley and Ilkley as part of the Airedale hospital team, for their incredible and tireless work to help and support patients. I would like to understand whether the petition’s aims are part of the Government’s ambitions under their 10-year health plan. This poignant petition asks the Government for the right things, and, given the amount of correspondence I have received from petitioners and residents across my constituency, it has my backing.

You will not be surprised to hear, Mr Vickers, that it is a pleasure to serve under your chairship today. I thank my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for the way in which she introduced the debate and engaged with the petitioners.

The UK’s breast screening programme is one of the greatest successes of our NHS. In Scotland, around 130 lives are saved each year through screening alone. The programme provides critical early diagnoses, improving treatment options and patient outcomes. Even in the worst cases, early diagnosis can give women precious extra time with their family and friends. However, the petition asks whether the current programme is enough. The screening used for those between the ages of 50 and 71 does not account for the fact that one in six people diagnosed with breast cancer each year are below the age of 50. Many more are diagnosed later, and tragically, diagnoses often come too late.

Studies from the USA show that women who are diagnosed with breast cancer when they are under 40 are 40% more likely to die from their cancer, and in the UK, breast cancer is the leading killer of women between the ages of 29 and 40. Worse still, the charity CoppaFeel! tells us that when women present to a healthcare professional with breast cancer symptoms, they are “routinely dismissed”—no doubt as menopausal, as often happens to women—creating missed opportunities for treatment. Sadly, those missed opportunities will only increase with the rate of breast cancer in young women, which, as we have heard, is already increasing. Although rates of breast cancer are increasing in all age groups, the incidence rates in younger women are growing faster than the rates in older women. Those facts should lead us to ask whether it is time to reconsider our current approach to screening.

I recognise that the petition’s proposal to transition to annual screening and to lower the screening age could present significant challenges for the NHS. Annual testing would require significant additional resources and patient buy in, and younger women’s breasts are often denser and therefore harder to scan, which throws up more anxiety inducing false positives. However, those challenges should not discourage us from doing more to support these women. Innovations such as the seven minute risk assessments proposed by CoppaFeel! could help us to improve and expand targeted screening to younger women with a predisposition to breast cancer, and increased resources and publicity will drive up uptake among all women.

To close, I want to recognise the work of CoppaFeel! and Asda, as well as the House of Hope in my constituency. The report CoppaFeel! published on the impact of a breast cancer diagnosis on younger patients has informed many hon. Members in this debate, and I pay tribute to its partnership with Asda, in their Tickled Pink campaign. In Edinburgh South West last year, Asda Chesser donated £2,700 to the House of Hope in Gorgie. The House of Hope is Scotland’s first bespoke support centre for those living with cancer. It provides care rather than treatment, and supports women and their families. The centre provides life enhancing support every day, and the impact it has had in just its first year of operation cannot be understated.

The House of Hope would not be what it is without the commitment of its founder, Lisa Fleming, who, since her diagnosis at age 33, has been a tireless advocate for the cancer community. I am proud to call her my constituent. This morning, she and her mother—both are formidable—were on my Facebook page, trying to influence this debate. When I met her mother a week or two ago, I was reminded that when a young woman gets breast cancer, her loved ones, including her children and parents, are affected by it. That wider economic impact should be taken into account in our decision making.

It is through work like Lisa’s and, I hope, a renewed commitment from the Minister to improve our screening processes that we can continue to take steps against this terrible disease. I feel obliged to put a question to the Minister, and I hope she will promise me this. The next time she visits Edinburgh, will she stop her ministerial limousine at the House of Hope and pay Lisa a visit?

It is a pleasure to serve under your chairship, Mr Vickers. I thank the hon. Member for North Ayrshire and Arran (Irene Campbell) for presenting this important debate and the Minister for attending. I congratulate Gemma Reeves on organising this well supported petition and her campaigning on this very important issue. Being diagnosed with breast cancer is a bewildering and terrifying experience for far too many people, as many of us know. Breast cancer is the most common cancer in the UK. Around 60,000 people are diagnosed with breast cancer every year, and one in seven women will receive such a diagnosis during their lifetime. Early diagnosis is crucial. Detecting breast cancer sooner gives people the best chance of successful treatment and ultimately saves lives.

In my own case, I had to visit my GP twice before receiving a diagnosis. Between visits to the GP, the cancer spread to my lymph glands. The result of that spread still causes issues for me today, 18 years later. Thankfully my treatment was successful, but many others are not so fortunate because of delays in diagnosis. More than 95% of people diagnosed at stage 1 survive for at least five years compared with around 25% diagnosed at stage 4. That is why breast screening is so important.

The Marmot review estimated that the current screening programme prevents around 1,300 deaths every year, yet uptake remains too low, particularly in England, where rates lag behind the devolved nations and pre pandemic levels. Almost 30% of eligible women are not attending screening appointments. Around 600,000 women are missing the opportunity for early detection. Cancer Research UK found that concerns about pain are the most common barrier to attending. Others miss invitations, struggle to find the time or remain unconvinced of the benefits. Uptake is even lower in deprived communities, worsening existing inequalities in cancer outcomes. In England in 2025, screening uptake was 65% in the most deprived areas, compared with 75% in the least deprived areas.

The Government need to work on ideas to improve access to screening, particularly where uptake is lowest. Simple measures such as follow up invitations, culturally appropriate information and community based pop up screening services could make a real difference by meeting people where they are and at times that work for them. Will the Minister outline what plans the Government might have to increase screening uptake, particularly through community based services?

Improving uptake alone, though, is not enough. Serious workforce shortages and outdated equipment continue to delay diagnosis and treatment. Too much diagnostic equipment is ageing or even no longer fit for purpose. Many areas face shortages of radiotherapy capacity, faulty mammography equipment and insufficient staff to operate machines consistently. I have long called for greater investment in the NHS workforce, including during a debate in Westminster Hall last year. Although I welcome the Government’s national cancer plan, the commitment to provide 28 new radiotherapy machines falls well short of what is actually needed. Instead, the Government should be looking to provide at least 200 additional machines; that is what is required to tackle the backlog and ensure timely diagnosis and treatment. That is why my Liberal Democrat colleagues and I have called for a 10-year capital investment programme so that every cancer patient can benefit from faster, more accurate diagnostics and treatment.

What further plans do the Government have to invest in both the workforce and the equipment needed to improve breast cancer outcomes? We know that breast cancer screening works and that early diagnosis saves lives. Now the Government must ensure that everyone can benefit by improving uptake and providing the investment that our cancer services urgently need.

It is a pleasure to serve under your chairship, Mr Vickers. I thank my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for introducing this debate. I also thank all those who signed the petition and who have campaigned to raise awareness of this issue.

Breast cancer is one of the most common cancers in women in the UK. While there may be a lot of talk of statistics today, the impact of breast cancer is not a number on a chart or in a table; it is real life, and it is heartbreaking. It is a mother, daughter, sister, friend or colleague—almost every one of us knows someone whose life has been touched by this terrible disease. We know that the earlier breast cancer is detected, the greater the chance of successful treatment, and screening remains the route most likely to find breast cancer early. As we have heard, the 2012 Marmot review found that our screening programmes prevent 1,300 deaths from breast cancer every year, so I understand where the petitioners are coming from. Even one misdiagnosis feels like one too many. That concern is real, and it deserves to be taken seriously.

The stories of my friends Laura Turnbull, mum of Louis, Josh, Alfie and Zac and wife of Richard, and Anne Wise, mum of Louis and Lauren, have brought this home to me all too painfully. Both were under 50 and had reached remission at least once, but both sadly saw their cancer return in different forms, tragically cutting their lives short. I send love to their families—especially to Anne’s, because it is her funeral on Saturday. Sadly, Laura and Anne are not alone. More than a decade ago, I lost another friend, Fiona Bennett. Her breast cancer also reached her before she was 50. These stories are powerful reminders that breast cancer does not only affect older women, and explain why so many people are asking what more can be done.

That is why we should follow the science. As new evidence emerges, technology improves and we learn more about detecting breast cancer earlier and more accurately, our screening programme should continue to evolve to ensure that it delivers the very best benefits to our patients. Alongside that, we must not lose sight of the opportunity we already have. In 2025, only 70% of Portsmouth women aged 53 to 70 had attended a breast screening in the last 36 months. That is more than 4% behind the average of local authority districts in the south east, and the gap has been widening in recent years. Whatever changes may come in the future, we must also make sure that every woman who is currently eligible takes up the opportunity to be screened.

Improving the uptake of screening among those already eligible must be an absolute priority, so I would like to ask the Minister how we are identifying barriers and what we are doing to break them down. Sadly, we know that levels of deprivation directly affect screening attendance. That is why I welcome the Government’s new cancer plan, which will include targeted campaigns to improve screening uptake in deprived and underserved communities, helping to ensure that where people live or what they earn does not determine their chance of cancer diagnosis. Can the Minister say more about that?

Unfortunately, after 14 years of Conservative mismanagement, the NHS has not met its cancer target since 2014. England’s cancer survival rates have slipped behind those of many comparable countries. That is not good enough. It is so important that, as we discuss expanding access to breast screening, we also recognise that the quickest way to undermine that principle would be to move towards an insurance based healthcare system, as advocated by Reform UK, which could alienate even more people and stop them taking up that screening opportunity for fear of what it would cost.

Labour has set out ambitious reforms to cancer diagnosis and treatment, which are expected to save more 320,000 lives over the plan’s lifetime. More scanners and advances in diagnostic technology mean that we will have a real opportunity to diagnose cancers early and improve outcomes by shifting more healthcare into our communities and neighbourhoods. We can make screening more accessible and less daunting so that Portsmouth women will attend, whether through health hubs on the high street or having opening hours at weekends, in the early morning or evening, which would widen access. I would welcome working with the Minister on how we can get these diagnosis centres open in Portsmouth North, so that we can raise attendance from 70% to 100%.

This debate is not about choosing between improving today’s screening programme and preparing for tomorrow —we must do both. We should continue to listen to clinicians, researchers and campaigners, and be prepared to strengthen and adapt programmes as the evidence develops. At the same time, we must ensure that every woman entitled to screening because of age, family history or symptoms is encouraged and supported to attend. The screening programme works only if people use it. Every invitation accepted is another chance to detect cancer early, another opportunity for less invasive treatment, and another family spared devastating news.

If we continue to improve the science, widen access where the evidence supports it and ensure that more eligible women come forward, we will save more lives and spare many more families the heartbreak of Laura’s, Anne’s and Fiona’s.

It is a pleasure to serve under your chairship, Mr Vickers. I thank my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for leading this debate.

Gemma Reeves is a breast cancer nurse at the Queen Elizabeth The Queen Mother, my local hospital in Margate. She started a petition that I noticed on my Instagram feed a few months ago, which calls on the NHS to establish annual mammograms for 40-year old women. I noticed that it was getting a lot of traction on my feed and that a lot of people I knew were signing up to it. I explored it more and wanted to understand where the policy would end up, but then—my colleagues will recognise this—it became another one of those campaigns I said I would do.

One day, however, I found that Gemma was up here in Westminster with her son, Mason, and I came to meet her in Central Lobby. She told me what she had seen as a breast cancer care nurse in the hospital in Margate, during the pandemic and since: an increase in the number of women under 50 presenting with breast cancer. What she saw corroborates research from CoppaFeel! showing that breast cancer in young women is on the rise. She became increasingly concerned that the people she was caring for could have had screening that might have meant that, when they finally presented at hospital, their cancer was not so advanced. More than half of all breast cancer cases in the UK occur in people outside the national screening age—one in six are under 50.

From having those conversations with Gemma, and since with the Minister, I know that many challenges come with tackling breast cancer in women under 50. We need to work out the best way of tackling breast cancer in younger women. I am delighted that the Minister met me, Gemma and her friends, who were previously her patients. They have become not just her friends but her co campaigners, because they have experienced getting breast cancer under 50 and also wish that there had been some kind of screening to identify their cancer earlier.

We and many people contributing to this debate know that screening is currently designed for older women; mammograms are designed for women over 50. Therefore, if we are looking for a way of screening young women, we may need to think about and explore different kinds of technologies, from MRIs to ultrasound.

We also need to avoid false positives, as many of my colleagues have referred to. More women could end up fearing that they have breast cancer than actually have it if we introduce screening that produces false positives. We also need to recognise that, for many people, having an early test or check in that includes things such as family history would enable them and their medical carers to spot the risks they are exposed to and decide whether they should go for early screening.

Whatever the answer, it is clear that the status quo is not acceptable, because it is not built for young people. It is also clear that the evidence on the occurrence of breast cancer in under-50s is out of date; the most recent evidence is from 2018. Therefore, I am absolutely delighted that Gemma has been able to come forward and lead this campaign, gathering so many signatures to her petition from across the country, particularly in east Kent. I hope that the Minister will take seriously her request not only to publish the evidence, but to act on it, and to find new ways of making sure that women younger than the current screening age of 50 are able to access screening to get their breast cancer spotted early.

One of our big missions in our mandate from the election was to tackle healthcare via prevention. Around 30% of breast cancers could be prevented through exercise, diet and alcohol control. Additionally, the earlier women are screened, the more likely it is that we can prevent illness and death. That is why I have supported Gemma in this campaign. I hope the Minister will be sympathetic to exploring further ways of making sure that young women can be confident that breast screenings will spot cancer early.

It is a pleasure to serve under your chairmanship, Mr Vickers. I commend my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for leading this important debate and setting out the argument so clearly. I welcome the petition upon which the debate is predicated, and I recognise the calls from the petitioners, including the 141 signatories from Mid Cheshire.

Any measures that can increase breast cancer diagnosis rates, improve treatment options, enhance survival and, ultimately, save lives must be considered carefully. A diagnosis of breast cancer is devastating at any stage, but when it comes too late—when opportunities for early detection have been missed—the consequences are profound and irreversible.

Behind every statistic is a person, a family, a future altered forever. Today, I want to focus on the story of my constituent Sarah. Sarah was identified as being at higher risk of developing breast cancer due to her family history. In March 2020, she took the responsible step of seeing her GP and was referred for genetic testing, but as the covid-19 pandemic took hold, all non symptomatic breast screening, including family history assessments, was paused locally.

Sarah did everything right—she repeatedly followed up and sought answers, and was assured that she remained on a waiting list—but the appointment never came. Just over a year later, in May 2021, Sarah found a lump in her breast. Following investigations, she was diagnosed with triple negative breast cancer, an aggressive form of the disease. She underwent a mastectomy and chemotherapy, but even then her journey was marked by delays in test results and in the start of treatment. Less than a year later, in April 2022, Sarah discovered another lump. This time, the cancer had spread. What had once been treatable was now incurable; treatment could only manage it.

Again, delays followed—delays that no patient in such a fragile situation should ever endure. Nevertheless, Sarah wrote: “I would like to make it clear that I very much appreciate the care and support I have received despite the obvious overwhelming and continuing pressures on the NHS. Almost every single NHS employee has been extremely kind and professional and have made many difficult experiences at least a little easier. They appear to share many of the frustrations.”

Tragically, Sarah passed away in May 2024, aged just 46.

Even in the face of her own mortality, Sarah fought for change. She spoke out about her experience and called for improvements to ensure timely testing and treatment. Crucially, she argued that non symptomatic screening must never again be paused, even in times of crisis, because early diagnosis saves lives.

Sarah was absolutely right to highlight the significant impact that pausing non symptomatic screening had on early diagnosis, treatment options and patient outcomes. Any disruption to early detection has lasting and devastating consequences. Her call for us to ensure that future pandemic preparedness protects vital screening services must be heeded. After Sarah’s death, her husband Dave carried forward her campaign with extraordinary courage and determination. His advocacy, born of grief, was powerful and inspiring, but tragically Dave took his own life a few short months ago.

We cannot let their story end here. Their experience lays bare the cost of delay, the cost of inaction and the cost of systems that fail to prioritise early diagnosis. We must act by strengthening screening programmes, ensuring resilience in times of crisis and delivering timely care for every patient. Let this be the legacy of Sarah and Dave: a legacy not of loss alone, but of change. We owe it to them, and to every family, to ensure that no one else endures what they did.

It is a pleasure to serve under your chairship, Mr Vickers. I thank the hon. Member for North Ayrshire and Arran (Irene Campbell) for leading this important petition debate on NHS breast screening.

It is hard to follow the passionate speech by the hon. Member for Mid Cheshire (Andrew Cooper), but this is important, because there are about 60,000 new cases of breast cancer in the UK each year. Breast cancer represents 15% of all new cancer cases and 30% of all new female cancer cases. It is the most common type of cancer among women: a woman is diagnosed with breast cancer every nine minutes and there are approximately 11,200 deaths due to breast cancer each year in the UK. The human costs behind those statistics cannot be overstated. In the short span of today’s debate, 10 women will be diagnosed with breast cancer and two will tragically lose their lives to the disease.

Over recent decades, we have made huge strides in the diagnosis and treatment of breast cancer. It is remarkable that approximately 76% of women now survive for 10 years or more following their diagnosis. But as with any cancer, diagnosing breast cancer early remains vital and saves lives. Breast screening remains the most effective way to detect cancer at an early stage, which is also when treatment is most likely to succeed. More than 95% of people diagnosed at stage 1 will survive for at least five years, compared with about 25% diagnosed at stage 4.

The Marmot review estimated that the current screening programme prevents about 1,300 deaths a year. In 2024-25, about 2.75 million women aged 50 to 71 were invited to be screened—a 10% increase on the previous year—and 2.15 million of them took the offer up. Nearly 20,000 women had breast cancer detected through that screening, but as those figures highlight, around 600,000 women did not take up the essential offer of breast cancer screening.

Recent screening data reveals an alarming trend of women not attending their first screening appointment. The impact of not taking up the screening offer only compounds the issue. Women who do not attend their first breast cancer screening appointment are much less likely to take up subsequent screening invitations. In 2024-25, only 20.9% of women in England who had never previously taken up screening invitations attended, compared with the 89.1% uptake among women who had been screened in the last five years. Since the creation of the modern NHS breast screening programme, uptake for first time screening invitations has never reached 70%.

Had the screening uptake level reached the NHS achievable standard target of 80% in 2024-25, over a quarter of a million more women would have undergone routine screening, and that would have resulted in an estimated additional 2,228 cases of breast cancer being found. The scale of the missed opportunity to catch more cancer early is unacceptable, and women and their loved ones are paying the tragic price. I urge anyone who is eligible to take up the offer of breast cancer screening.

The Liberal Democrats are clear that so much more must be done to ensure that every eligible woman attends screening when invited, particularly in England, where uptake is lagging behind the devolved nations and pre pandemic levels. There are many reasons why women do not attend their breast cancer screening appointments, including misconceptions about the screening process and breast cancer, the fear of receiving a diagnosis, and cultural beliefs and attitudes. Others may not be able to attend due to everyday challenges such as limited transport, clashing work schedules or the burden of caring responsibilities. Health inequalities also affect screening uptake. Women from ethnic minority communities, those living in disadvantaged areas and women with disabilities often face additional barriers that reduce their access to breast screening services.

What actions are the Labour Government taking to improve screening uptake nationally, particularly among disenfranchised women? What steps are the Government actively taking to support pop up screening initiatives in community settings, and what is being done to ensure that those vital health services are meeting people where they are and at times that work for them? What steps is the Minister taking to ensure that women are able to receive the best screening test for their individual health needs? That might include, for example, providing women with an increased risk of breast cancer with an ultrasound if they are unable to have an MRI or they have dense breasts. That is particularly relevant to younger women with an increased risk, for whom an ultrasound will provide greater accuracy in screening their dense breast tissue. Mammograms can struggle to identify cancer in dense breasts, as cancers and dense tissue present in exactly the same way on imaging.

The Liberal Democrats are also very concerned that so much NHS equipment, including diagnostic and scanning equipment, is out of date and decrepit. A quarter of England’s 280 radiotherapy machines are now operating beyond their 10-year lifespan, with a further 26 due to exceed the recommended lifespan by 2027. England has fewer radiotherapy machines than comparable European countries. Radiotherapy UK’s research reveals that England has just 4.8 linear accelerator machines per million population, well behind France at 8.5 and Italy at 6.9.

Radiotherapy lacks clear accountability. While responsibility for commissioning it sits with integrated care boards, freedom of information requests found that around 70% of ICBs do not have a named person responsible for radiotherapy. Access to radiotherapy is well below international expectations. Around 52% to 53% of cancer patients are estimated to need radiotherapy, but only around 35% receive it in England. In some areas, the figure is as low as 22%. Radiotherapy also has the longest waiting times. Only around four in 10 patients—and, in some areas of the country, as few as two in 10— receive radiotherapy on time.

Whether it is radiotherapy deserts or the mammogram machine glitch that left 7,000 women in parts of Essex without a screening service for almost two months, breast cancer patients are routinely being let down by faulty and inaccessible equipment. That is unacceptable and we must take action now. To address that, the Liberal Democrats are campaigning for a 10-year capital investment programme, under which all patients, including women with breast cancer, would benefit from easier access to newer, quicker and more accurate machines.

Alongside screening, speed and quality of treatment are central to increasing breast cancer survival rates. The Liberal Democrats would introduce a guarantee that 100% of patients would be able to start treatment within 62 days of urgent referral. We would also replace the ageing radiotherapy machines and increase their numbers to guarantee that no one must travel ridiculous distances to receive the treatment that they desperately need. Currently, 3.4 million people in England live further away from a radiotherapy centre than the NHS target of 45 minutes.

Taking those steps now is vital. We need to prepare our local cancer services for the future, as demand is increasing. Cancer cases are expected to rise by about 30% by 2040, and the new national screening programme is likely to identify more patients who need curative radiotherapy treatment. Without urgent action, the existing pressures on radiotherapy services will only worsen. We would also recruit more cancer nurses so that every patient had a dedicated specialist supporting them throughout their treatment, and halve the time for new treatments to reach patients by expanding the capacity of the Medicines and Healthcare products Regulatory Agency.

The future looks bright, with early pilots and trials using AI to analyse mammograms showing promising signs of potential improvement in both the speed and the accuracy of screening, but we must support our life sciences sector much more to champion vital research and innovation. The Liberal Democrats would pass a cancer survival research Act requiring the Government to co ordinate and ensure funding for research into the cancers with the lowest survival rates.

I want to reflect on the 10 women who were diagnosed with breast cancer and the two who will have tragically lost their lives to the disease in the short span of today’s debate. For them and the thousands of people—mostly women, but also men—living with breast cancer and their loved ones, I urge the Minister to carefully consider the important points and perspectives raised in the debate.

It is a pleasure to serve under your chairmanship, Mr Vickers. I congratulate Gemma Reeves on bringing forward the petition and the hon. Member for North Ayrshire and Arran (Irene Campbell) on introducing this important debate. It has been very moving to hear so many stories from hon. Members on both sides of the House reminding us of the human cost of this disease.

Breast cancer is very common, as other Members have said, affecting one in seven women during their lifetime. The Minister and I have had a number of debates in this Chamber about various diseases and forms of cancer. One of the core principles we often discuss is that early diagnosis saves lives. Cancer Research UK says that 85% of women who live more than 10 years after a diagnosis of breast cancer were diagnosed at stage 1 or 2 —the earlier stages to be diagnosed at. It was for that reason, and on that principle, that the UK introduced the world’s first national screening programme for breast cancer in 1988. Since then, much has changed. In particular, survival rates have improved dramatically. Now, 76.6% live more than 10 years; the figure was very much lower in the 1980s.

There are still some issues with screening, however, as hon. Members have said. One is that women with denser breasts find it more difficult to locate lumps, and when doing mammograms, it can be more difficult to locate cancerous tumours. Will the Minister update the House on what work has been done on using ultrasounds and MRIs to identify tumours in women with denser breasts? I understand that the National Screening Council is looking at this subject in detail. When is it due to report its findings to the Minister, and when does she intends to bring them to the House?

The effectiveness of treatment has improved, but the risk of overtreatment is higher in younger women. The incidence of the disease is increasing in younger and older women: the Cancer Research UK website says that the rate has increased by 12% in women aged between 25 and 49, and by 72% in women aged between 65 and 69. Should younger women therefore now receive screening, and should older women receive more frequent screening?

The cancer plan, which the Government published earlier this year, said that they will engage with manufacturers to look at mammograms that are more accessible to those with a physical disability, who at the moment struggle to receive their screening. Will the Minister update the House on the engagement she has had with manufacturers and on the progress that has been made?

The age trial in Oxford is looking at women aged between 47 and 49, and between 71 and 73—the ages just outside the current range of screening. I understand that early results are due in December 2026. Has the Minister had any indication of the results yet, and is she preparing for any results that come forward? Has she engaged with the people running that important trial?

Community diagnostic centres, which were initiated by the previous Government and rolled out across the country, provide screening close to people’s homes, which makes it much easier for them to attend. Will the Minister update us on how she is improving the number of CDCs available across the country?

The Government have talked about the shifts that they want to produce in healthcare, one of which is about prevention. According to the Cancer Research UK website, 23% of breast cancer cases are preventable. Will the Minister update us on what she is doing to reduce the number of preventable cases of breast cancer?

Many hon. Members have talked about attendance at screening tests. The hon. Member for Epsom and Ewell (Helen Maguire) spoke about some of the reasons why women do not attend screening. It is important that we understand why about a third of women do not attend. It is only by understanding what puts women off and makes them not attend that we can improve the services so that more women do attend. It was sobering to hear how many lives could be saved if more women attended screening. How are we making screening more accessible for women? Are we ensuring that women know that it is happening and that they need it? Do they understand the benefits of it? I would be interested to hear the Minister’s thoughts.

Another shift relates to the digital NHS. AI provides us with a number of ways to improve breast cancer screening and treatment. It could help us to understand who should be invited to screening and how often, and it can help when looking at mammogram scans. A few years ago, the Health and Social Care Committee visited Stanford in California and looked at the AI there. We saw a study comparing two radiology consultants looking at a scan, two AI computers using two different programmes, and a person and an AI computer. It discovered that the person and the AI computer were the most accurate. That can help to reduce the number of people we need in the workforce and, importantly, can improve the accuracy of screening results.

That brings me on to the workforce. We know that the Government have a workforce plan, although its publication has been much delayed. We have been told repeatedly over the past few weeks that it has moved to “imminent” status—imminent being quicker than soon—but we do not know when imminent is. Does that mean it will be published before the summer, or do we need to wait for the new Prime Minister to make a decision? It would be helpful to know that from the Minister. As we heard about radiology and radiotherapy, the workforce is incredibly important. We need a thorough plan, otherwise we will have recommendations from the NSC for screening and no people to provide that care.

I also wanted to raise with the Minister the Lobular Moon Shot Project. We have discussed before the importance of research into lobular breast cancer, which is more difficult to diagnose and treat. The last time we spoke about this, the Minister was looking at research projects that the Government could fund to identify new treatments and ways of screening for this disease, hopefully saving lives. Will she update us on how she is getting along with that?

Much of my time at the moment is spent with another Health Minister—the Minister for Secondary Care, the hon. Member for Bristol South (Karin Smyth)—in Committee Room 9, debating the Health Bill. That is where I will be tomorrow. The Bill relates to one of the important organisational factors in screening. At the moment, screening programmes are generally organised by NHS England, which is being abolished. NHS England and the Department of Health and Social Care wrote a letter in March saying that commissioning responsibility will be directly delegated to ICBs, in the same way that they are currently delegated to NHSE, by the Secretary of State. Does the Minister expect that to cause any disruption to the breast screening programme?

Integrated care boards have had their budgets cut by 50% just as they are asked to take on this work. We know that they are merging and reorganising in cells. The Government’s plans are that they should follow the mayoral authority boundaries, but the mergers that have taken place so far do not follow those boundaries. There is therefore a risk that we will need reorganisation all over again. Does the Minister think that that will have an effect on the screening programme? If so, what is she doing to mitigate that effect to ensure that as many people as possible get the very best screening and we can reduce the number of people suffering from the disease?

The screening programme offers a real opportunity to diagnose, treat early and save lives, but it needs to be delivered well. We need to ensure that the right people get the right type of screening at the right age, and at the right frequency. I will be interested to hear the Minister’s response.

How long do I have to speak? I have a lot to get through; let us see if I can make it.

I start by thanking my hon. Friend the Member for North Ayrshire and Arran (Irene Campbell) for opening the debate on behalf of the Petitions Committee. I also thank my hon. Friend the Member for East Thanet (Ms Billington), her constituent Gemma, Gemma’s son, Mason, and the other ladies in the Public Gallery today for their campaigning on this petition and for gathering so many signatures that we can debate it. I pay tribute to them and thank them for joining us. I was very pleased to meet them last month to discuss this important issue.

I pay tribute to my predecessor, my hon. Friend the Member for West Lancashire (Ashley Dalton). I commend her constant courage in speaking so openly about her experience of breast cancer. I send my very best wishes to her throughout her ongoing treatment.

Behind all the figures we are discussing today, there are women, men, families and communities who have been affected by breast cancer in the most difficult and personal of ways. I pay tribute to NHS staff in breast screening services across the country, who work tirelessly to ensure that women and men are offered this important preventive measure.

Last year, our highly effective NHS breast screening programme screened nearly 2 million women. Each year, the programme is estimated to save 1,300 lives, but we must be honest about the scale of the challenge. Around 11,500 women still die from breast cancer each year. Many thousands more go through treatment, with all the fear, uncertainty and disruption that brings for them and the people who love them. That is why I am clear: we need to do more and will do more.

The national cancer plan published earlier this year sets out how we will improve outcomes for breast cancer patients. We will speed up diagnosis and treatment, ensure that patients can access the latest treatments and technology and, ultimately, drive up this country’s cancer survival rates. The plan commits to rolling out breast pain clinics nationally by the end of the year. It also builds on successful initiatives such as mobile breast screening units. Cancer alliances will receive funding to work proactively with local communities and providers so that more cancers are diagnosed earlier.

I will now speak to points that were raised by my hon. Friend the Member for Edinburgh South West (Dr Arthur), the hon. Member for Wokingham (Clive Jones), my hon. Friends the Members for Broxtowe (Juliet Campbell) and for Portsmouth North (Amanda Martin), and the Liberal Democrat spokesperson, the hon. Member for Epsom and Ewell (Helen Maguire)—there might have been others, but those are the names I scribbled down. They raised issues about serving ethnic minority communities as well as underserved, deprived communities. Building on successful initiatives such as mobile breast screening, as I mentioned, cancer alliances will receive funding and work proactively with local communities and providers to improve early diagnosis rates. They will focus on increasing people’s awareness of symptoms, and support primary care to spot the signs of cancer early. The work will also include reducing the gap in screening uptake between the most and least deprived areas. There will be particular efforts to reach ethnic minority communities and underserved groups because no one should be left behind.

The NHS also runs its “Help Us, Help You” campaign in England, which helps to increase knowledge of breast cancer symptoms and address barriers to acting on them, as well as encouraging people to come forward to see their GP as soon as possible. I understand why many people ask whether screening should begin at a younger age. It is a deeply human question that is often asked by people who have seen the impact of breast cancer at first hand. We are looking carefully at the evidence, but the picture is complex. I will come on to everything about that that has been raised.

As we have heard, younger women tend to have denser breast tissue, which can make mammography less effective. Screening can save lives, but it can also cause harm through false positives, unnecessary tests, avoidable anxiety and overdiagnosis. That is why decisions must be made carefully and on the basis of robust evidence. My hon. Friends the Members for Doncaster East and the Isle of Axholme (Lee Pitcher), for Broxtowe and for Edinburgh South West, as well as other colleagues, no doubt, raised that issue. As we know, some women will have denser breast tissue and unfortunately that makes mammography less effective because a potential cancer can be harder to spot. We are working to find the best solutions to that problem.

A study called BRAID—breast screening risk adaptive imaging for density—is looking into whether supplementary imaging techniques like MRI or ultrasound could be used for women with dense breast tissue. The independent UK National Screening Committee is in contact with the researchers and reviews the evidence as it becomes available. Ministers in the Department and across the Government will consider its recommendations as soon as they are made.

A number of colleagues asked about the AgeX breast screening trial, which is the biggest trial of its kind ever undertaken. It will provide robust evidence about the effectiveness of screening in age groups above and below the current screening age. The trial has been looking at the effectiveness of offering some women one extra screening between the ages of 47 and 49 and one between the ages of 71 and 73. AgeX is the biggest trial of its kind ever to be undertaken and will provide robust evidence about the effectiveness, benefits and harms of screening in those age groups. The UK NSC will review the publication of the AgeX extension trial when it reports. The trial began in 2009, and results are expected in 2027, something the hon. Member for Keighley and Ilkley (Robbie Moore) asked about.

Screening trials require extended follow up periods to generate robust evidence on whether screening reduces disease or death, while also assessing any potential long term harms. The UK NSC continuously monitors emerging evidence through horizon scanning and maintains active engagement with international peers. Should robust evidence regarding the extension of breast screening age thresholds become available, the committee will look at it right away. In the meantime, NHS England has produced a suite of public facing information resources, communicating that women, especially those aged 71 or over, can have screening every three years if they so wish.

The hon. Member for Keighley and Ilkley also asked why we do not screen annually. The three year intervals of the national breast screening programme are based on a successful Swedish trial. The frequency of screening balances the risk of harm from over diagnosis with the benefits of early detection, and women at high risk of breast cancer are often called more frequently.

I want a bit of clarity from the Minister, because the petitioners are calling on the Government to lower the age at which women are first called for breast cancer screening to 40 and to roll out screening on an annual basis rather than every three years. I know that they are not intending to do that, because we have seen the written response from them in advance of the debate, but what further evidence do the Government need to be able to achieve what the petitioners are asking?

As I said, the AgeX trial has been running since 2009 and has been researching the efficacy of providing breast cancer screening to people above and below the current screening age. It is due to report next year, so hopefully it will provide the further evidence that is necessary. It is already in train. These decisions are not taken lightly, as I am sure the hon. Gentleman appreciates.

The shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson), asked me about AI. We are supporting the early detection using information technology in health, or EDITH, trial. It will test new AI technologies that could enable one specialist—rather than two, as is currently required—to complete a mammogram screening process, increasing capacity in the screening system while maintaining patient safety.

We are entering a new era in science and technology. Advances in data, genomics and predictive analytics will allow the NHS to deliver care that is more personalised, more proactive and better matched to each person’s individual risk. New tools, such as liquid biopsies and other non invasive tests, may help us to detect cancer much earlier, and often before symptoms appear. The NHS is preparing to seize those breakthroughs so that patients can benefit from the full power of modern innovation.

The national cancer plan has identified priority areas to accelerate access to new technologies, including artificial intelligence assisted interpretation of pathology images for suspected breast cancer diagnosis. We will continue to horizon scan for better methods of screening and to build the evidence base for any future changes. Our ambition is clear—to save more lives, to diagnose cancer earlier and to do so in a way that brings more benefit than harm.

I am interested in the possibilities of AI helping with detection and speeding up that process, freeing up resources to be directed into earlier detection by focusing on screening for younger women. If we are to harness the potential of AI, surely the first thing that we should do is to redirect the resources that are saved into ensuring that we can save more lives, potentially those of the young women who have campaigned so strongly on this petition.

Yes; saving more lives and freeing up resources is exactly what we should be doing. In relation to the AgeX trial evidence and other evidence that is being looked at, that will be happening within the next year. Hopefully for my hon. Friend and others here today and the campaigners, the evidence will be looked at and, if it is strong enough, things will change.

Colleagues raised a number of other issues that I want to touch on. The hon. Member for Wokingham, chair of the all party parliamentary group on breast cancer, always reminds us that it is not just women who are affected. Sixty thousand people a year are diagnosed with breast cancer, and a small proportion of that number will be men. It is always important that we remember that, and he is doing an amazing job as chair of the all party group. If I am here and the hon. Member for Sleaford and North Hykeham (Dr Johnson), who speaks for the Opposition, is here, the hon. Gentleman is often here as well—we have become a regular trio in these debates on a Monday.

I must mention my hon. Friend the Member for Mid Cheshire (Andrew Cooper), who gave a very emotional speech about his constituent Sarah and her husband David. What happened was so tragic. I thank my hon. Friend for sharing that, and I want him to know that all of us here having heard it already means that it was not in vain. He said that he wanted to make sure that their story had been heard—how tragic it was, its consequences, and how long lasting the effect of this awful disease is, not just on those who suffer, but on the wider family.

My hon. Friend the Member for Portsmouth North asked me about cancer waiting times more broadly, and I cannot let this moment go without stressing that cancer patients are now getting diagnosed in the shortest time on record. I am pleased to report that.

The hon. Member for Sleaford and North Hykeham raised the very important issue of women with physical disabilities. We have spoken about this before. The NHS has an obligation to make appropriate accommodations for people with disabilities, as I know she is aware. Unfortunately, however, some mammography machines are not a good design for people in wheelchairs and those who cannot support their own torso. For women for whom mammography is not an option, a physical exam can still be offered; and where a GP is concerned about the findings following a physical exam, the woman can be referred for further diagnostic tests. The NHS is talking with manufacturers about amending the design of mammography machines, and NHS England is considering whether alternative testing tools could be used instead of a mammogram in those specific circumstances.

I can reassure the hon. Lady that the workforce plan is still imminent; I have nothing further to add on that. She mentioned lobular breast cancer and the Moon Shot project. As she is aware, in April Lord Vallance, the Minister for Science, Innovation, Research and Nuclear, and I, alongside NIHR and MRC representatives, met the Lobular Moon Shot Project team to discuss how best to progress research in this area.

Following that meeting, a scientific roundtable on lobular breast cancer was organised earlier this month. Lord Vallance hosted the roundtable, and Professor Patrick Chinnery, executive chair of the MRC, chaired a discussion considering the challenges and opportunities for progress in invasive lobular breast cancer research. The NIHR is actively encouraging high quality, ambitious research proposals on lobular breast cancer, having launched a highlight notice in late 2025. We hope that the team will make an application for that.

I cannot finish my speech without stating one message as clearly as I can. If hon. Members or their constituents are, at any time, worried about breast cancer symptoms, such as a lump, an area of thickened tissue in the breast or any change in how their breasts look or feel, no matter what age they may be, I say this: “Please do not wait to be offered screening. Please contact your GP at any stage.” Coming forward early, as we know—and as Gemma and her friends know more than most—can make all the difference. I want to make sure that message goes out loud and clear.

It has been a privilege to open and close such an important debate. We have heard from many Members and the Minister about how important early diagnosis and treatment are for breast cancer, and how key it is that we tackle this issue quickly and effectively. We have also heard about health inequalities and deprivation, and how they can impact the take up of screening opportunities. We must do more to address that.

The NHS 10-year plan has committed to diagnosing 75% of cancers early by 2028, and the national cancer plan has a 75% five year survival target for all cancers. This is an area that is very important to so many people across the UK, and we must do all we can as a Government to improve recovery and survival from cancer, particularly the most common type of cancer in women.

I would like to finish by thanking the petitioner, Gemma Reeves, again and congratulating her on gathering over 106,000 signatures, which is a great achievement.

I would also like to thank Lily Parsey, Sophie Conway and Lily Ewin from CoppaFeel!, Nele Gewert and Hannah Maybour from Breast Cancer Now, Cristina Visintin and Ros Given Wilson from the UK National Screening Committee, and Professor Sacha Howell and Sarah Hindmarch from Manchester University for meeting me and my team before this debate.

Finally, as always, I thank the staff of the Petitions Committee, who work tirelessly every week to make sure that these debates go ahead in such a smooth and effective way.

Question put and agreed to. Resolved, That this House has considered e petition 742179 relating to NHS breast screening.

Sitting adjourned.